Nyrada Inc (ASX:NYR) Cholesterol-Lowering Program Pathway To Phase I

Nyrada (ASX:NYR) has provided an update to the market regarding its cholesterol lowering drug program which is due to enter human clinical trials in the second half of 2022. Charles River Laboratories has been appointed to conduct safety pharmacology and toxicology studies in the US during the first half of 2022. These studies are a precursor to the phase 1 clinical trial which will be conducted in Australia and involve approximately 56 healthy volunteers to evaluate the safety, tolerability and efficacy of Nyrada’s cholesterol-lowering drug candidate.

The company also announced it had filed a new PCT patent application for a new generation of cholesterol lowering compounds, broadening protection of Nyrada’s PCSK9 inhibitor technology.

Canary Capital believes that 2022 will be an exciting year for NYR as it heads into the clinic with its cholesterol lowering drug and progresses its brain injury program.

ASX RELEASE 22.12.2021


Contact Us